Numerai Gp LLC Arvinas, Inc. Transaction History

Numerai Gp LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$19.64 - $28.21 $2.31 Million - $3.32 Million	-117,613 Reduced 90.47%	12,395 $243 Million
Q2 2023 Aug 11, 2023	BUY	$21.73 - $31.43 $2.27 Million - $3.28 Million	104,409 Added 407.86%	130,008 $3.23 Billion
Q1 2023 May 12, 2023	BUY	$26.15 - $37.26 $669,413 - $953,818	25,599 New	25,599 $699 Million

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Numerai Gp LLC, based on Form 13F filings with the SEC.

Stay updated on Numerai Gp LLC with notifications on news.